RNA Protein RBM39 Drives Liver Cancer by Boosting DNA Repair Efficiency
New research reveals how RBM39 protein enhances DNA repair in liver cancer cells, suggesting combination therapy targets.
Summary
Chinese researchers discovered that RNA-binding protein RBM39 promotes liver cancer progression by enhancing DNA repair efficiency. Using liver cancer cell lines, they found RBM39 stabilizes OGG1 mRNA, a key DNA repair enzyme. When RBM39 was knocked down or degraded with the drug indisulam, DNA repair dropped significantly and cancer cells became more vulnerable to oxidative damage. The study suggests combining indisulam with oxidative stress inducers like KBrO3 could be an effective liver cancer treatment strategy.
Detailed Summary
This study reveals a critical mechanism by which RNA-binding motif protein 39 (RBM39) promotes hepatocellular carcinoma (HCC) progression through enhanced DNA repair capabilities. The research addresses a significant clinical need, as HCC accounts for 90% of primary liver cancers with a 5-year survival rate below 10% for advanced cases.
Researchers analyzed liver cancer patients from The Cancer Genome Atlas and conducted extensive laboratory experiments using Hep3B and HCC-LM3 liver cancer cell lines. They employed multiple techniques including comet assays for DNA damage assessment, fluorescence-based plasmid reactivation assays for base excision repair (BER) efficiency measurement, and various molecular biology approaches to examine protein-RNA interactions.
Key findings demonstrate that RBM39 significantly enhances BER efficiency in liver cancer cells. When RBM39 was knocked down via siRNA or degraded using the drug indisulam, BER efficiency dropped substantially compared to controls. Conversely, RBM39 overexpression increased BER efficiency approximately 2-fold. The mechanism involves RBM39 binding to and stabilizing OGG1 mRNA, a crucial DNA glycosylase that initiates repair of oxidative DNA damage. Under oxidative stress induced by KBrO3, RBM39-depleted cells showed significantly increased DNA damage as measured by comet assay tail moments.
The clinical implications are promising. The study demonstrates that combining indisulam (which degrades RBM39) with oxidative stress inducers like KBrO3 creates a synergistic anti-cancer effect both in cell culture and xenograft mouse models. This combination therapy approach could overcome the enhanced DNA repair capabilities that help liver cancer cells survive treatment. The research provides mechanistic insight into why targeting DNA repair pathways represents an attractive cancer therapeutic strategy.
Key Findings
- RBM39 overexpression increased BER efficiency approximately 2-fold in liver cancer cell lines compared to controls
- RBM39 knockdown or indisulam-induced degradation significantly reduced BER efficiency in both Hep3B and HCC-LM3 cells
- Liver cancer patients with high BER gene expression (C3 subtype) showed shortest overall survival and highest RBM39 levels
- Comet assay revealed significantly increased DNA damage tail moments in RBM39-depleted cells under oxidative stress
- RBM39 directly binds and stabilizes OGG1 mRNA, a key DNA repair enzyme, through RNA-protein interactions
- Combination treatment with indisulam plus KBrO3 showed synergistic anti-cancer effects in xenograft mouse models
- BER efficiency decreased more markedly with 48-hour versus 24-hour indisulam treatment in cancer cells
Methodology
The study used liver cancer cell lines Hep3B and HCC-LM3 with various genetic manipulations including siRNA knockdown, drug-induced protein degradation with indisulam, and overexpression constructs. BER efficiency was measured using fluorescence-based plasmid reactivation assays with methylene blue-damaged pEGFP-N1 plasmids. DNA damage was assessed via alkaline comet assays analyzing tail moments in at least 50 cells per condition. Statistical analyses included Student's t-tests and Mann-Whitney U tests with appropriate error measurements.
Study Limitations
The study was conducted primarily in cell culture models with limited validation in animal xenograft models. The research focused on two specific liver cancer cell lines, which may not represent the full heterogeneity of human hepatocellular carcinoma. Long-term safety and efficacy of the proposed combination therapy approach requires further clinical validation. The authors did not report significant conflicts of interest or funding limitations that might bias the results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.